The C2P Chemo-Proteomic Platform initiative to address new challenges in drug design:
On July 1st 2013, MEDIT and Felix Concordia have launched the C2P Chemo-Protein Platform initiative to provide a complete software solution to better mine altogether biostructures, structure activities and chemical libraries at PDB, Pubchem and multi-million compound levels. We strongly believe this is opening new perspectives in drug discovery and target profiling by combining knowledges from experimental data with existing predictive models.
C2P architecture allows to cross-mine with interactive 1D/2D/3D/ND queries a data repositories of biostructures, structure activities and chemical libraries. Navigation conjointly in binding sites, ligands, subpockets, fragments 2D/3D similarities including anti-targets, unwanted chemistry, and in-house data provides a new smart experience to highlight selectivity mechanisms. C2P initiative now includes MED-SuMo-GUI (Medit SA) to detect/superpose similar 3D protein surface interactions, MEDP-Fragmentor (from MEDIT) to deconvolute protein-ligand structure in pocket-fragment interactions, MEDP-Site-Classifier (Medit SA) to classify the full Protein Data Bank according to pocket similarities, FcLigand (Felix Concordia SARL) to explore 1D/2D/3D ligand similarities, FcBioisostere (Felix Concordia SARL) to better profile your compound by using bioisosteric replacement, and the C2P-API open source advanced programming interface.
MEDIT SA, a privately held software company, has developed a large experience on solutions to superpose protein binding sites for functional annotation, off-target identification, drug repurposing, and fragment-based drug design. Felix Concordia SARL is providing consistent software components to mine large set of data in life science.